A28 Therapeutics

Executive Summary

A28 Therapeutics is a clinical-stage biopharmaceutical company pioneering a novel platform of targeted oncolytic peptide conjugates for cancer treatment. Its lead compound, AT-101, selectively binds to LHRH receptors overexpressed on cancer cells, delivering a lytic peptide that disrupts cell membranes, inducing rapid tumor necrosis. This mechanism offers a potentially broad therapeutic window across multiple solid tumors and hematological malignancies. Founded in 2021 and based in Cambridge, MA, the company is advancing its pipeline toward clinical proof-of-concept. With a differentiated approach that combines tumor targeting with a potent cytotoxic peptide, A28 aims to address significant unmet needs in oncology, particularly for patients with limited treatment options. The platform's modular design also enables future expansion into other peptide-conjugate therapies. As a private entity, A28 has not disclosed financial details, but its innovative strategy positions it as a potential contender in the targeted cancer therapy space.

Upcoming Catalysts (preview)

• H2 2026Initial Phase 1 data from AT-101 in solid tumors30% success
• Q4 2026IND submission for hematological malignancy indication50% success
• Q3 2026Series A financing round completion70% success